US OptionsDetailed Quotes
VXRT250117P2000
- 1.44
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
1.44Open1.44Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV24.32%PremiumJan 17, 2025Expiry Date1.26Intrinsic Value100Multiplier-3DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.58Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Vaxart Stock Discussion
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
Tuesday, 14th January at 8:00 am
COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort 30-day safety data
Norovirus program to proceed with Phase 1 study following scientific advisory board and FDA feedback; Trial to initiate the first half of 2025 with topline data expected as early as mid-2025
New avian...
📊⚡️📊
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
Monday, 13th January at 7:55 pm
Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data
The company plans to progress the trial to enrollment of 10,000 participants, upon favorable review from the U.S. Food and Drug Administration (FDA) and upon Biomedical Advanced Research...
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator —
— The sentinel cohort is being funded as part of the Phase 2b NextGen COVID-19 clinical trial, valued at up to $456 million through the Rapid Response ...
No comment yet